Sow Samba O, Muhsen Khitam, Nasrin Dilruba, Blackwelder William C, Wu Yukun, Farag Tamer H, Panchalingam Sandra, Sur Dipika, Zaidi Anita K M, Faruque Abu S G, Saha Debasish, Adegbola Richard, Alonso Pedro L, Breiman Robert F, Bassat Quique, Tamboura Boubou, Sanogo Doh, Onwuchekwa Uma, Manna Byomkesh, Ramamurthy Thandavarayan, Kanungo Suman, Ahmed Shahnawaz, Qureshi Shahida, Quadri Farheen, Hossain Anowar, Das Sumon K, Antonio Martin, Hossain M Jahangir, Mandomando Inacio, Nhampossa Tacilta, Acácio Sozinho, Omore Richard, Oundo Joseph O, Ochieng John B, Mintz Eric D, O'Reilly Ciara E, Berkeley Lynette Y, Livio Sofie, Tennant Sharon M, Sommerfelt Halvor, Nataro James P, Ziv-Baran Tomer, Robins-Browne Roy M, Mishcherkin Vladimir, Zhang Jixian, Liu Jie, Houpt Eric R, Kotloff Karen L, Levine Myron M
Centre pour le Développement des Vaccins, Bamako, Mali.
Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
PLoS Negl Trop Dis. 2016 May 24;10(5):e0004729. doi: 10.1371/journal.pntd.0004729. eCollection 2016 May.
The importance of Cryptosporidium as a pediatric enteropathogen in developing countries is recognized.
Data from the Global Enteric Multicenter Study (GEMS), a 3-year, 7-site, case-control study of moderate-to-severe diarrhea (MSD) and GEMS-1A (1-year study of MSD and less-severe diarrhea [LSD]) were analyzed. Stools from 12,110 MSD and 3,174 LSD cases among children aged <60 months and from 21,527 randomly-selected controls matched by age, sex and community were immunoassay-tested for Cryptosporidium. Species of a subset of Cryptosporidium-positive specimens were identified by PCR; GP60 sequencing identified anthroponotic C. parvum. Combined annual Cryptosporidium-attributable diarrhea incidences among children aged <24 months for African and Asian GEMS sites were extrapolated to sub-Saharan Africa and South Asian regions to estimate region-wide MSD and LSD burdens. Attributable and excess mortality due to Cryptosporidium diarrhea were estimated.
Cryptosporidium was significantly associated with MSD and LSD below age 24 months. Among Cryptosporidium-positive MSD cases, C. hominis was detected in 77.8% (95% CI, 73.0%-81.9%) and C. parvum in 9.9% (95% CI, 7.1%-13.6%); 92% of C. parvum tested were anthroponotic genotypes. Annual Cryptosporidium-attributable MSD incidence was 3.48 (95% CI, 2.27-4.67) and 3.18 (95% CI, 1.85-4.52) per 100 child-years in African and Asian infants, respectively, and 1.41 (95% CI, 0.73-2.08) and 1.36 (95% CI, 0.66-2.05) per 100 child-years in toddlers. Corresponding Cryptosporidium-attributable LSD incidences per 100 child-years were 2.52 (95% CI, 0.33-5.01) and 4.88 (95% CI, 0.82-8.92) in infants and 4.04 (95% CI, 0.56-7.51) and 4.71 (95% CI, 0.24-9.18) in toddlers. We estimate 2.9 and 4.7 million Cryptosporidium-attributable cases annually in children aged <24 months in the sub-Saharan Africa and India/Pakistan/Bangladesh/Nepal/Afghanistan regions, respectively, and ~202,000 Cryptosporidium-attributable deaths (regions combined). ~59,000 excess deaths occurred among Cryptosporidium-attributable diarrhea cases over expected if cases had been Cryptosporidium-negative.
The enormous African/Asian Cryptosporidium disease burden warrants investments to develop vaccines, diagnostics and therapies.
隐孢子虫作为发展中国家儿童肠道病原体的重要性已得到认可。
分析了全球肠道多中心研究(GEMS)的数据,这是一项为期3年、在7个地点开展的中重度腹泻(MSD)病例对照研究,以及GEMS - 1A(一项为期1年的MSD和轻度腹泻[LSD]研究)。对年龄小于60个月的12110例MSD患儿和3174例LSD患儿以及21527名按年龄、性别和社区匹配的随机选择对照的粪便进行隐孢子虫免疫分析检测。通过聚合酶链反应(PCR)鉴定隐孢子虫阳性标本子集的种类;GP60测序鉴定人源型微小隐孢子虫。将非洲和亚洲GEMS站点年龄小于24个月儿童中隐孢子虫所致腹泻的年合并发病率外推至撒哈拉以南非洲和南亚地区,以估计全区域的MSD和LSD负担。估计了隐孢子虫腹泻所致的归因死亡率和超额死亡率。
隐孢子虫与24个月以下儿童的MSD和LSD显著相关。在隐孢子虫阳性的MSD病例中,人隐孢子虫检出率为77.8%(95%置信区间,73.0% - 81.9%),微小隐孢子虫为9.9%(95%置信区间,7.1% - 13.6%);检测的微小隐孢子虫中92%为人源基因型。非洲和亚洲婴儿中,隐孢子虫所致MSD的年发病率分别为每100儿童年3.48例(95%置信区间,2.27 - 4.67)和3.18例(95%置信区间,1.85 - 4.52),幼儿中分别为每100儿童年1.41例(95%置信区间,0.73 - 2.08)和1.36例(95%置信区间,0.66 - 2.05)。每100儿童年相应的隐孢子虫所致LSD发病率,婴儿中为2.52例(95%置信区间,0.33 - 5.01)和4.88例(95%置信区间,0.82 - 8.92),幼儿中为4.04例(95%置信区间,0.56 - 7.51)和4.71例(95%置信区间,0.24 - 9.18)。我们估计,在撒哈拉以南非洲和印度/巴基斯坦/孟加拉国/尼泊尔/阿富汗地区,年龄小于24个月的儿童中,每年分别有290万和470万例由隐孢子虫引起的病例,以及约20.2万例由隐孢子虫引起的死亡(两个地区合计)。在隐孢子虫所致腹泻病例中,与病例为隐孢子虫阴性时的预期相比,发生了约5.9万例超额死亡。
非洲/亚洲巨大的隐孢子虫疾病负担需要投资研发疫苗、诊断方法和治疗手段。